There are only few studies concerning about long-term effect of growth hormone (GH) replacement therapy on bone mineral density and bone microstructure. To assess effect of GH replacement therapy on bone mineral density (BMD) and trabecular bone score (TBS) in adult GH deficient (AGHD) subjects over period of 10 years. From 2005 to 2018, a prospective study of AGHD patients was conducted in national referral center for treatment of GHD. All patients received subcutaneous recombinant human GH in an IGF 1-normalizing regimen once a day. Lumbar spine (L-spine) and total hip (TH) BMD using Hologic densitometers were measured at baseline and every two years during treatment with rhGH. TBS was derived from L1-L4 DXA using iNsight® software (Medimaps, France) at each time point. Periods of measurement were baseline, year 2; 4; 6; 8 and 10. In total, 63 patients (38 males, 25 females, mean age 25.1±16 years) were included in the study. After 10 years of GH treatment, IGF-1 significantly increased (~35 %), with greatest increase at year 2. During 10-year follow-up, L-spine BMD increased approximately of 7 % (NS). TH BMD increase of 11 % during follow-up (p=0.0003). The greatest increment of BMD was achieved at year 6 on both sites, L-spine (+6 %) and TH BMD (+13 %) (p<0.05). There was no significant change of TBS during whole follow-up. In this study, sustaining positive effect of GH replacement therapy on bone density in subjects with adult GH deficiency over 10 years of follow-up was observed. The study did not show effect on TBS, as indirect measure of trabecular bone microarchitecture.

Comenius University Faculty of Medicine 5th department of Internal Medicine University Hospital Bratislava Bratislava Slovakia

See more in PubMed

ALLO MIGUEL G, SERRACLARA PLA A, PARTIDA MUNOZ ML, MARTINEZ DIAZ-GUERRA G, HAWKINS F. Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center. Ther Adv Endocrinol Metab. 2016;7:93–100. doi: 10.1177/2042018816643908. PubMed DOI PMC

APPELMAN-DIJKSTRA NM, CLAESSEN KM, HAMDY NA, PEREIRA AM, BIERMASZ NR. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf) 2014;81:727–735. doi: 10.1111/cen.12493. PubMed DOI

ARWERT LI, DEIJEN JB, MULLER M, DRENT ML. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm Behav. 2005a;47:343–349. doi: 10.1016/j.yhbeh.2004.11.015. PubMed DOI

BARAKE M, ARABI A, NAKHOUL N, EL-HAJJ FULEIHAN G, EL GHANDOUR S, KLIBANSKI A, TRITOS NA. Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis. Endocrine. 2018;59:39–49. doi: 10.1007/s12020-017-1440-0. PubMed DOI

BIERMASZ NR, HAMDY NA, JANSSEN YJ, ROELFSEMA F. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J Clin Endocrinol Metab. 2001;86:3079–3085. doi: 10.1210/jcem.86.7.7669. PubMed DOI

BRAVENBOER N, HOLZMANN P, De BOER H, BLOK GJ, LIPS P. Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone. 1996;18:551–557. doi: 10.1016/8756-3282(96)00069-5. PubMed DOI

BRAVENBOER N, HOLZMANN PJ, TER MAATEN JC, STUURMAN LM, ROOS JC, LIPS P. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res. 2005;20:1778–1784. doi: 10.1359/JBMR.050613. PubMed DOI

BREDELLA MA, LIN E, GERWECK AV, LANDA MG, THOMAS BJ, TORRIANI M, BOUXSEIN ML, MILLER KK. Determinants of bone microarchitecture and mechanical properties in obese men. J Clin Endocrinol Metab. 2012;97:4115–4122. doi: 10.1210/jc.2012-2246. PubMed DOI PMC

CLANGET C, SECK T, HINKE V, WUSTER C, ZIEGLER R, PFEILSCHIFTER J. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf) 2001a;55:93–99. doi: 10.1046/j.1365-2265.2001.01284.x. PubMed DOI

CLANGET C, SECK T, HINKE V, WUSTER C, ZIEGLER R, PFEILSCHIFTER J. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf) 2001b;55:93–99. doi: 10.1046/j.1365-2265.2001.01284.x. PubMed DOI

COLSON A, BROOKE AM, WALKER D, BESSER GM, CHEW SL, GROSSMAN AB, JENKINS PJ, DRAKE WM, MONSON JP. Growth hormone deficiency and replacement in patients with treated Cushing’s Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Horm Res. 2006;66:257–267. doi: 10.1159/000095168. PubMed DOI

CONWAY GS, SZARRAS-CZAPNIK M, RACZ K, KELLER A, CHANSON P, TAUBER M, ZACHARIN M. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol. 2009;160:899–907. doi: 10.1530/EJE-08-0436. PubMed DOI

DAVIDSON P, MILNE R, CHASE D, COOPER C. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2004;60:92–98. doi: 10.1111/j.1365-2265.2004.01935.x. PubMed DOI

De BOER H, BLOK GJ, VOERMAN HJ, PHILLIPS M, SCHOUTEN JA. Serum lipid levels in growth hormone-deficient men. Metabolism. 1994;43:199–203. doi: 10.1016/0026-0495(94)90245-3. PubMed DOI

ELBORNSSON M, GOTHERSTROM G, BOSAEUS I, BENGTSSON BA, JOHANNSSON G, SVENSSON J. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2012;166:787–795. doi: 10.1530/EJE-11-1072. PubMed DOI PMC

FINKELSTEIN JS, NEER RM, BILLER BM, CRAWFORD JD, KLIBANSKI A. Osteopenia in men with a history of delayed puberty. N Engl J Med. 1992;326:600–604. doi: 10.1056/NEJM199202273260904. PubMed DOI

GOTHERSTROM G, BENGTSSON BA, BOSAEUS I, JOHANNSSON G, SVENSSON J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol. 2007;156:55–64. doi: 10.1530/eje.1.02317. PubMed DOI

JORGENSEN AP, FOUGNER KJ, UELAND T, GUDMUNDSEN O, BURMAN P, SCHREINER T, BOLLERSLEV J. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm IGF Res. 2011;21:69–75. doi: 10.1016/j.ghir.2011.01.001. PubMed DOI

KRISTENSEN E, HALLGRIMSSON B, MORCK DW, BOYD SK. Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency. Int J Endocrinol. 2012;2012:294965. doi: 10.1155/2012/294965. PubMed DOI PMC

KUZMA M, JACKULIAK P, KILLINGER Z, VANUGA P, PAYER J. Issues related to secondary osteoporosis associated with growth hormone deficiency in adulthood (in Slovak) Vnitr Lek. 2017;63:658–661. doi: 10.36290/vnl.2017.128. PubMed DOI

KUZMA M, KUZMOVA Z, ZELINKOVA Z, KILLINGER Z, VANUGA P, LAZUROVA I, TOMKOVA S, PAYER J. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res. 2014;24:22–28. doi: 10.1016/j.ghir.2013.12.001. PubMed DOI

KUŽMA M, BINKLEY N, BEDNÁROVÁ A, KILLINGER Z, VAŇUGA P, PAYER J. TRABECULAR BONE SCORE CHANGE DIFFERS WITH REGARD TO 25(OH)D LEVELS IN PATIENTS TREATED FOR ADULT-ONSET GROWTH HORMONE DEFICIENCY. Endocr Pract. 2016;22:951–958. doi: 10.4158/EP151183.OR. PubMed DOI

KUŽMA M, KILLINGER Z, JACKULIAK P, VAŇUGA P, HANS D, BINKLEY N, PAYER J. Pathophysiology of growth hormone secretion disorders and their impact on bone microstructure as measured by trabecular bone score. Physiol Res. 2019;68:S121–S129. doi: 10.33549/physiolres.934303. PubMed DOI

LINDSEY RC, MOHAN S. Skeletal effects of growth hormone and insulin-like growth factor-I therapy. Mol Cell Endocrinol. 2016;432:44–55. doi: 10.1016/j.mce.2015.09.017. PubMed DOI PMC

McCLOSKEY EV, ODEN A, HARVEY NC, LESLIE WD, HANS D, JOHANSSON H, BARKMANN R, BOUTROY S, BROWN J, CHAPURLAT R, ELDERS PJM, FUJITA Y, GLUER CC, GOLTZMAN D, IKI M, KARLSSON M, KINDMARK A, KOTOWICZ M, KURUMATANI N, KWOK T, LAMY O, LEUNG J, LIPPUNER K, LJUNGGREN O, LORENTZON M, MELLSTROM D, MERLIJN T, OEI L, OHLSSON C, PASCO JA, RIVADENEIRA F, ROSENGREN B, SORNAY-RENDU E, SZULC P, TAMAKI J, KANIS JA. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res. 2016;31:940–948. doi: 10.1002/jbmr.2734. PubMed DOI

MOLITCH ME, CLEMMONS DR, MALOZOWSKI S, MERRIAM GR, SHALET SM, VANCE ML, STEPHENS PA. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006;91:1621–1634. doi: 10.1210/jc.2005-2227. PubMed DOI

ROSÉN T, EDÉN S, LARSON G, WILHELMSEN L, BENGTSSON BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993;129:195–200. doi: 10.1530/acta.0.1290195. PubMed DOI

ROSEN T, WILHELMSEN L, LANDIN-WILHELMSEN K, LAPPAS G, BENGTSSON BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 1997;137:240–245. doi: 10.1530/eje.0.1370240. PubMed DOI

ROTA F, SAVANELLI MC, TAUCHMANOVA L, SAVASTANO S, LOMBARDI G, COLAO A, DI SC. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J Endocrinol Invest. 2008;31:94–102. doi: 10.1007/BF03345574. PubMed DOI

SAGGESE G, BARONCELLI GI, BERTELLONI S, BARSANTI S. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab. 1996;81:3077–3083. doi: 10.1210/jcem.81.8.8768878. PubMed DOI

YANG H, YAN K, XU Y, WANG L. Effects of 24 weeks of growth hormone treatment on bone microstructure and volumetric bone density in patients with childhood-onset adult GH deficiency. Int J Endocrinol. 2020:9201979. doi: 10.1155/2020/9201979. PubMed DOI PMC